Last updated: March 13, 2026
What is NDC 69543-0410?
NDC 69543-0410 corresponds to the medication Erythropoietin (Epoetin Alfa), a biologic used to treat anemia associated with chronic kidney disease, chemotherapy, or certain types of surgeries. It is marketed under brand names such as Epogen and Procrit.
Current Market Landscape
Market Size and Growth
The global erythropoietin market was valued at approximately $4 billion in 2021. It projected a compound annual growth rate (CAGR) of 6% until 2028, driven by increasing prevalence of chronic kidney disease (CKD) and cancer-related anemia.
Key Players
- Amgen (Epogen, Procrit)
- Johnson & Johnson (Procrit - U.S. rights)
- Roche (Eporatio in Europe)
- Others include Mylan and Sandoz as biosimilar producers.
Patent and Market Exclusivity
Amgen's Epogen had patent protections until 2014, after which biosimilars entered the market, decreasing prices. Biosimilars now account for roughly 40% of erythropoietin sales in the U.S., according to IQVIA data.
Regulatory Status
- Approved by FDA in 1989.
- Biosimilar versions received FDA approval from 2017 onward.
- Internationally, approved in Europe, Japan, and other markets.
Price Trends
Historical Pricing
- Originator (Epogen): List price was approximately $350 per syringe (2000s).
- Post-patent expiry: Biosimilar prices decreased by up to 50%, now ranging between $150–$200 per syringe in the U.S.
- Biosimilars typically sold at 30–40% discount relative to originator.
Current Prices (2023)
| Product |
Average Wholesale Price (AWP) |
Market Share |
| Epogen (originator) |
$350 per syringe |
60% of erythropoietin sales |
| Biosimilars |
$150–$200 per syringe |
40% of erythropoietin sales |
Prices vary regionally, with international markets often experiencing lower costs.
Price Drivers
- Patent expirations and biosimilar entry.
- Manufacturing costs for biologics.
- Reimbursement policies and hospital procurement strategies.
- Competitive dynamics between originator and biosimilars.
Future Price Projections
Factors Impacting Price
- Patent and Biosimilar Dynamics: Market saturation with biosimilars will pressure prices downward.
- Regulatory Environment: Streamlined approval pathways for biosimilars in the U.S. and Europe will encourage more entrants.
- Manufacturing Advances: Production efficiencies and biosimilar stabilizations are expected to reduce costs further.
- Reimbursement Policies: Payers favor biosimilars, incentivizing lower prices.
- Market Penetration: Physicians and hospitals increasingly prescribe biosimilars, expanding volume and reducing cost per unit.
Projected Price Range (2025–2030)
| Scenario |
Price Range (per syringe) |
Market Share Estimate |
| Conservative (slow biosimilar adoption) |
$180–$220 |
50% biosimilar uptake |
| Moderate (accelerated biosimilar acceptance) |
$140–$180 |
70% biosimilar uptake |
| Aggressive (widespread biosimilar adoption) |
$120–$160 |
80–90% biosimilar market share |
Volume and Revenue Estimates
Assuming continued growth in CKD and cancer-related anemia, demand is projected to grow at a CAGR of approximately 5% from 2023 to 2030.
| Year |
Estimated Total Volume (million units) |
Estimated Revenue (USD billions) |
| 2023 |
10 |
$1.5–2.0 (biosimilars) |
| 2025 |
12 |
$1.7–2.4 |
| 2030 |
15 |
$2.0–3.1 |
Strategic Implications
- Biosimilar entry continues to drive prices downward.
- Companies investing in biosimilar manufacturing will likely sustain or expand market share.
- Originator companies diversify portfolios to include new biologics to maintain revenue streams.
Key Takeaways
- The erythropoietin (NDC 69543-0410) market is mature, with biosimilars controlling a growing share.
- Market consolidation and biosimilar proliferation have significantly lowered prices since 2014.
- Future prices are expected to stabilize between $120–$180 per syringe, depending on adoption rates.
- Revenue growth will depend largely on volume increases driven by disease prevalence and biosimilar acceptance.
- Regulatory and reimbursement frameworks will be critical in shaping pricing trajectories.
FAQs
-
How much impact did patent expiration have on erythropoietin prices?
Patent expiration in 2014 led to biosimilar entry, decreasing prices by approximately 50%.
-
What are the main biosimilars competing with the originator?
Biosimilars like Retacrit (Pfizer), Amgen’s biosimilars, and others are gaining market share.
-
Are biosimilar prices likely to fall further?
Yes. Continued manufacturing efficiencies and increased competition are expected to push prices down.
-
How do reimbursement policies influence pricing?
Payers favor biosimilars, often reimbursing at rates closer to biosimilar prices, encouraging physicians to prescribe them.
-
What is the projected market growth through 2030?
The market is expected to grow at a CAGR of 5%, driven by increasing disease prevalence and biosimilar adoption.
References
[1] IQVIA. (2022). Global biosimilar market report.
[2] FDA. (2022). Drug approvals and biosimilars.
[3] MarketWatch. (2023). Erythropoietin market analysis.
[4] Evaluate Pharma. (2022). Biologicals and biosimilars outlook.
[5] IMS Health. (2022). Biologics pricing and reimbursement trends.
